oxaliplatin (eloxatin) Report issue

Small molecule Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Oxaliplatin (brand name Eloxatin), a new generation of platinum derivatives discovered by Prof Kidani in 1976 at Nagoya University in Japan, was licensed-in and developed by Debiopharm. Eloxatin is typically administered in combination with fluorouracil and leucovorin for the adjuvant treatment of stage III colon cancer and for the treatment of advanced carcinoma of the colon or rectum. Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo 1,2-diaminocyclohexane (DACH) platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific.   NCATS

  • SMILES: [Pt++].[O-]C(=O)C([O-])=O.N[C@@H]1CCCC[C@H]1N
  • InChIKey: ZROHGHOFXNOHSO-BNTLRKBRSA-L
  • Mol. Mass: 397.292
  • ALogP: Missing data
  • ChEMBL Molecule:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1.1055 - $81.6600

Australia

$15.3044 - $30.6088
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

1,2-diaminocyclohexane platinum oxalate | 1,2-diamminocyclohexane(trans-1)oxolatoplatinum(ii) | act 078 | act-078 | amt2003 | cis-oxalato-(trans-l)-1,2-diaminocyclohexane-platinum(ii) | diaminocyclohexane oxalatoplatinum | eloxatin | eloxatine | folfirinox | folfox | folfox-4 | jm-83 | l-ohp | l-ohp cpd | l-plat | mbp-426 | oxalato-(1,2-cyclohexanediamine)platinum ii | oxalatoplatin | oxalatoplatinum | oxaliplatin | oxaliplatine | oxaliplatino | oxaliplatin, (sp-4-2-(1r-trans))-isomer | oxaliplatin, (sp-4-2-(1s-trans))-isomer | oxaliplatin, (sp-4-3-(cis))-isomer | oxaliplatinum | oxapliplatin | platinum(ii)-1,2-cyclohexanediamine oxalate | rp-54780 | sanofi brand of oxaliplatin | sanofi synthelabo brand of oxaliplatin | sr96669 | sr-96669

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue